Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California
Asterias Biotherapeutics Granted Orphan Drug Designation for AST-OPC1 for the Treatment of Acute Spinal Cord Injury
Blue Jay Gold Corp. Announces Engagement of Oak Hill Financial Inc. for Investor Relations and Retention of Haywood Securities for Market Making Services
QIMC Highlights Technical Advisory Role on First Atlas Matane Natural Hydrogen Project Following Quebec Parliamentary Committee Appearance
